Uromigos Live-Kidney Cancer
Advertisement
Brian moderates the panel that discusses and debates TKI vs Ipi/Nivo vs IO/TKI.
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
Dr. Hedyeh Ebrahimi of City of Hope describes her favorite presentations and discussions related to renal cell carcinoma.
Sumanta Pal, MD, FASCO, from City of Hope talks about new drugs and the ongoing TiNivo-2 trial for renal cell carcinoma.
David McDermott, MD talks about monotherapy and combination therapy for RCC and future advances in RCC treatment.
Tian Zhang gives a quick recap of the Frontline Therapy in RCC panel from The Uromigos Live & Unplugged.
Axel Bex gives a quick recap of the renal panel on adjuvant therapy in RCC from The Uromigos Live & Unplugged.
The Uromigos and a panel of RCC experts discuss data on perioperative therapy in RCC, and the next adjuvant therapy trials.
A panel of RCC experts discuss frontline therapy for kidney cancer, as well as where they see it headed in the next 5 years.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.